ABEONA THERAPEUTICS INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $5.8M | — | $3.5M | $1.4M | $3.0M |
| Operating income | -$89.4M | -$64.2M | -$47.1M | -$50.9M | -$89.8M |
| Operating expenses | — | $64.2M | $50.6M | $52.3M | $92.8M |
| Cost of revenue | $1.5M | — | — | — | — |
| Cash from operations | -$76.3M | -$56.0M | -$37.0M | -$43.5M | -$65.7M |
| Capital expenditure | $8.0M | $2.4M | $331,000 | $130,000 | $4.2M |
| Free cash flow | -$84.3M | -$58.5M | -$37.3M | -$43.6M | -$69.8M |
| Share repurchases | — | — | — | $25.0M | — |
| Impairments | — | — | — | $1.8M | $32.5M |
| Total assets | $219.6M | $108.9M | $64.0M | $64.2M | $79.6M |
| Total liabilities | $60.4M | $64.9M | $49.2M | $37.5M | $37.2M |
| Total debt | $20.0M | $20.0M | — | — | — |
Shares outstanding 57.0M · Free float 61.0%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.